New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)

Tanjala T. Gipson, Michael V. Johnston

Research output: Contribution to journalReview article

Abstract

Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the TSC1 or TSC2 genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.

Original languageEnglish (US)
Article number859
JournalF1000Research
Volume6
DOIs
StatePublished - 2017

Fingerprint

Tuberous Sclerosis
Sirolimus
Infantile Spasms
Seizures
Cyclic AMP Receptor Protein
Brain
Lymphangioleiomyomatosis
Angiomyolipoma
Astrocytoma
Autistic Disorder
Intellectual Disability
Psychiatry
Epilepsy
Kidney
Lung
Mutation
Genes

Keywords

  • Neuropsychiatric disorder
  • TSC1
  • TSC2
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND). / Gipson, Tanjala T.; Johnston, Michael V.

In: F1000Research, Vol. 6, 859, 2017.

Research output: Contribution to journalReview article

Gipson, Tanjala T.; Johnston, Michael V. / New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).

In: F1000Research, Vol. 6, 859, 2017.

Research output: Contribution to journalReview article

@article{7b2b4af7117646b7bf54d3918759f59d,
title = "New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)",
abstract = "Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the TSC1 or TSC2 genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.",
keywords = "Neuropsychiatric disorder, TSC1, TSC2, Tuberous sclerosis complex",
author = "Gipson, {Tanjala T.} and Johnston, {Michael V.}",
year = "2017",
doi = "10.12688/f1000research.11110.1",
volume = "6",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)

AU - Gipson,Tanjala T.

AU - Johnston,Michael V.

PY - 2017

Y1 - 2017

N2 - Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the TSC1 or TSC2 genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.

AB - Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the TSC1 or TSC2 genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.

KW - Neuropsychiatric disorder

KW - TSC1

KW - TSC2

KW - Tuberous sclerosis complex

UR - http://www.scopus.com/inward/record.url?scp=85024472009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024472009&partnerID=8YFLogxK

U2 - 10.12688/f1000research.11110.1

DO - 10.12688/f1000research.11110.1

M3 - Review article

VL - 6

JO - F1000Research

T2 - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 859

ER -